Publication | Closed Access
Sustained Efficacy and Reduced Hypoglycemia during One Year of Treatment with Vildagliptin Added to Insulin in Patients with Type 2 Diabetes Mellitus
82
Citations
0
References
2008
Year
Metabolic SyndromeDiabetes ManagementDrug-naïve PatientsInsulin ManagementDiabetesPharmacologyType 2Endogenous Glucagon-like Peptide-1Peptide TherapeuticsDiabetes ComplicationsHyperglycemiaPharmacotherapyInsulin DeliveryDiabetes MellitusMedicineInsulin SignalingMinimal HypoglycemiaVildagliptin Added
Vildagliptin is a potent and selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), which enhances endogenous glucagon-like peptide-1 (GLP-1) levels and improves islet function by increasing both α- and β-cell responsiveness to glucose [1] [2]. Vildagliptin produced statistically significant and clinically meaningful reductions in HbA1c values when given as monotherapy in drug-naïve patients [3] [4] or in combination with metformin [5] and pioglitazone [6], without weight gain and with minimal hypoglycemia. In patients with a long history of diabetes requiring insulin therapy, a population notoriously difficult to treat because therapeutic options are limited, the addition of vildagliptin to insulin therapy was associated with improved glycemic control and less hypoglycemia after six months of treatment [7].